Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>2024 marked our ninth year covering Equity Capital Markets in Asia-Pacific. In 2024, IPO volumes were mainly driven by India, even as Hong Kong showed signs of turning a corner.</li>
<li>We ended 2024 with an accuracy rate of 79.4% across 68 IPOs that we covered and 68.8% across 109 placements.</li>
<li>For those not familiar with our coverage, we aim to cover all IPOs and placements with a minimum deal size of US$100m across Asia-Pacific, including China ADRs.</li>
</ul>


2024 marked our ninth year covering Equity Capital Markets in Asia-Pacific. In 2024, IPO volumes were mainly driven by India, even as Hong Kong showed signs of turning a corner.
We ended 2024 with an accuracy rate of 79.4% across 68 IPOs that we covered and 68.8% across 109 placements.
For those not familiar with our coverage, we aim to cover all IPOs and placements with a minimum deal size of US$100m across Asia-Pacific, including China ADRs.


Aequitas 2024 IPOs and Placements Performance Review-India Driving Volumes as HK Shows Signs of Life

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 150 stocks over the last week. The average A-H premium was 95.0% as of Jan 3rd.</li>
<li>The average A-H premium changed by -2.1ppt week-on-week, led by information technology, utilities, materials and offset by consumer staples, communication services.</li>
<li>We highlight weekly changes in A-H premium for TEC, CanSinoBIO, SD GOLD, CRRC.</li>
</ul>


We analyse the changes of A-H premium on 150 stocks over the last week. The average A-H premium was 95.0% as of Jan 3rd.
The average A-H premium changed by -2.1ppt week-on-week, led by information technology, utilities, materials and offset by consumer staples, communication services.
We highlight weekly changes in A-H premium for TEC, CanSinoBIO, SD GOLD, CRRC.


A-H Premium Weekly (Jan 3rd):TEC, CanSinoBIO, SD GOLD, CRRC.

HK/China Equity Long-Short

Osbert Tang, CFA

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/vesync" target="_blank" data-smartkarma-citation="entities:31067:1" rel="noopener">Vesync (2148 HK)</a>'s major shareholders proposed to privatise at HK$5.60, a 33.3% premium to the pre-suspension price. This is the same as we calculated using the 3-year average P/B. </li>
<li>At such a price, it will sit at 7.6x PER for FY25F, a level that it only touched briefly 3 times in the last two years. </li>
<li>This PER is at a 25-30% discount to the sector and justified by its smaller size and lesser diversification. All in all, the proposed price looks fair and reasonable.</li>
</ul>



Vesync (2148 HK)'s major shareholders proposed to privatise at HK$5.60, a 33.3% premium to the pre-suspension price. This is the same as we calculated using the 3-year average P/B. 
At such a price, it will sit at 7.6x PER for FY25F, a level that it only touched briefly 3 times in the last two years. 
This PER is at a 25-30% discount to the sector and justified by its smaller size and lesser diversification. All in all, the proposed price looks fair and reasonable.


Vesync (2148 HK): Proposed Privatisation at HK$5.60 Fair and Reasonable

<ul>
<li>We analyse the changes of A-H premium on 150 stocks over the last week. The average A-H premium was 97.3% as of Dec 27th.</li>
<li>The average A-H premium changed by -3.2ppt week-on-week, led by consumer staples, information technology, real estate.</li>
<li>We highlight weekly changes in A-H premium for China Southern Air, Guolian Securities, GWM, SMIC, Pharmaron, ZTE, Tigermed.</li>
</ul>


We analyse the changes of A-H premium on 150 stocks over the last week. The average A-H premium was 97.3% as of Dec 27th.
The average A-H premium changed by -3.2ppt week-on-week, led by consumer staples, information technology, real estate.
We highlight weekly changes in A-H premium for China Southern Air, Guolian Securities, GWM, SMIC, Pharmaron, ZTE, Tigermed.


A-H Premium Weekly (Dec 27th): China Southern Air, Guolian Securities, GWM, SMIC, Pharmaron, ZTE

<ul>
<li>
<a href="https://www.smartkarma.com/entities/vesync" target="_blank" data-smartkarma-citation="entities:31067:1" rel="noopener">Vesync (2148 HK)</a>'s suspension may suggest privatisation by the Yang family (68.8% stake). With US$192m public float and US$216m net cash, out-of-pocket cash needed is limited. </li>
<li>1H24 is decent with a 37.5% earnings growth and 3.3pp margin expansion. The consensus forecast of 4.8% growth in 2H24 is conservative, providing a good opportunity for privatisation.</li>
<li>Benchmarking the take-out price to the 3-year average P/B will mean a 33% upside while the sector's average PER multiple implies ~70% higher than the pre-suspension price.</li>
</ul>



Vesync (2148 HK)'s suspension may suggest privatisation by the Yang family (68.8% stake). With US$192m public float and US$216m net cash, out-of-pocket cash needed is limited. 
1H24 is decent with a 37.5% earnings growth and 3.3pp margin expansion. The consensus forecast of 4.8% growth in 2H24 is conservative, providing a good opportunity for privatisation.
Benchmarking the take-out price to the 3-year average P/B will mean a 33% upside while the sector's average PER multiple implies ~70% higher than the pre-suspension price.


Vesync (2148 HK): A Potential Privatisation?

China

Midea Group Co., Ltd. manufactures and distributes home appliances. The Company produces water heaters, air conditioners, ventilation equipment, and consumer appliances. Midea Group also develops robotics and automation systems.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Midea Group (300 HK)

Aequitas 2024 IPOs and Placements Performance Review-India Driving Volumes as HK Shows Signs of Life

2024 marked our ninth year covering Equity Capital Markets in Asia-Pacific. We had an accuracy rate of 79.4% for IPOs and 68.8% for placements in...

Sumeet Singh

A-H Premium Weekly (Jan 3rd):TEC, CanSinoBIO, SD GOLD, CRRC.

We analyzed A-H premium changes in the past week and highlight A-H premium changes for TEC (688187 CH/3898 HK), CanSinoBIO (688185 CH/6185 HK), SD...

Ke Yan, CFA, FRM

Vesync (2148 HK): Proposed Privatisation at HK$5.60 Fair and Reasonable

Vesync's major shareholders propose to privatise it at HK$5.60, a 33.3% premium. We consider this a fair and reasonable price based on PER, P/B,...

Osbert Tang, CFA

A-H Premium Weekly (Dec 27th): China Southern Air, Guolian Securities, GWM, SMIC, Pharmaron, ZTE

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Southern Air, Guolian Securities, GWM, SMIC,...

Ke Yan, CFA, FRM

Vesync (2148 HK): A Potential Privatisation?

Vesync may be heading towards privatisation by the Yang family which owns a 68.8% stake. Using historical P/B average and sector PER average as...

Osbert Tang, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Aequitas 2024 IPOs and Placements Performance Review-India Driving Volumes as HK Shows Signs of Life

2024 marked our ninth year covering Equity Capital Markets in Asia-Pacific. We had an accuracy rate of 79.4% for IPOs and 68.8% for placements in...

Sumeet Singh

A-H Premium Weekly (Jan 3rd):TEC, CanSinoBIO, SD GOLD, CRRC.

We analyzed A-H premium changes in the past week and highlight A-H premium changes for TEC (688187 CH/3898 HK), CanSinoBIO (688185 CH/6185 HK), SD...

Ke Yan, CFA, FRM

Vesync (2148 HK): Proposed Privatisation at HK$5.60 Fair and Reasonable

​Vesync's major shareholders propose to privatise it at HK$5.60, a 33.3% premium. We consider this a fair and reasonable price based on PER, P/B,...

Osbert Tang, CFA

A-H Premium Weekly (Dec 27th): China Southern Air, Guolian Securities, GWM, SMIC, Pharmaron, ZTE

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Southern Air, Guolian Securities, GWM, SMIC,...

Ke Yan, CFA, FRM

Vesync (2148 HK): A Potential Privatisation?

​Vesync may be heading towards privatisation by the Yang family which owns a 68.8% stake. Using historical P/B average and sector PER average as...

Osbert Tang, CFA

Vesync's major shareholders propose to privatise it at HK$5.60, a 33.3% premium. We consider this a fair and reasonable price based on PER, P/B,...

Vesync may be heading towards privatisation by the Yang family which owns a 68.8% stake. Using historical P/B average and sector PER average as...